Pipeline

BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development. Our project portfolio as of November 17, 2022.

Alzheimer’s disease
Project
Lecanemab Clarity AD
Early Alzheimer's disease2
Partner
Eisai1
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
Lecanemab AHEAD 3-45
Preclinical (asymptomatic) Alzheimer's disease3
Partner
Eisai1
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
Lecanemab back-up
Partner
Eisai
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
BAN1503 (Trunc Abeta)
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
AD-BT2802
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
AD-BT2803 (Trunc Abeta with BT)
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
AD2603
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Alzheimer’s disease
Project
Partner
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory
Lecanemab Clarity AD
Early Alzheimer's disease2
Eisai1
Lecanemab AHEAD 3-45
Preclinical (asymptomatic) Alzheimer's disease3
Eisai1
Lecanemab back-up
Eisai
BAN1503 (Trunc Abeta)
AD-BT2802
AD-BT2803 (Trunc Abeta with BT)
AD2603
Parkinson’s disease
Project
BAN0805 (alpha-synuclein)
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Parkinson’s disease
Project
PD1601 (alpha-synuclein)
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Parkinson’s disease
Project
PD1602 (alpha-synuclein)
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Parkinson’s disease
Project
PD-BT2238 (alpha-synuclein with BT)
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Parkinson’s disease
Project
Partner
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory
BAN0805 (alpha-synuclein)
PD1601 (alpha-synuclein)
PD1602 (alpha-synuclein)
PD-BT2238 (alpha-synuclein with BT)
Other CNS disorders
Project
Lecanemab
Down's syndrome4
Traumatic brain injury4
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Other CNS disorders
Project
ND3014 (TDP43)
ALS
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Other CNS disorders
Project
ND-BT3814 (TDP-43 with BT)
ALS
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Other CNS disorders
Project
GD-BT6822 (GCase with BT)
Gaucher1
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Other CNS disorders
Project
Partner
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory
Lecanemab
Down's syndrome4
Traumatic brain injury4
ND3014 (TDP43)
ALS
ND-BT3814 (TDP-43 with BT)
ALS
GD-BT6822 (GCase with BT)
Gaucher1
Blood-brain barrier
Project
Brain Transporter (BT) technology platform
Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Blood-brain barrier
Project
Partner
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory
Brain Transporter (BT) technology platform

  1. Partnered with Eisai for Lecanemab for treatment of Alzheimer’s disease since 2007. Eisai entered partnership with Biogen regarding Ban2401 (lecanemab) in 2014.
  2. Mild cognitive function impairment due to Alzheimer’s disease and mild Alzheimer’s disease.
  3. Normal cognitive function with intermediate or elevated levels of amyloid-beta in the brain.
  4. Dementia and cognitive impairment associated with Down’s syndrome and with traumatic brain injury.